• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer.

作者信息

Guan Xiuwen, Ma Fei, Li Qiao, Chen Shanshan, Fan Ying, Wang Jiayu, Luo Yang, Zhang Pin, Li Qing, Xu Binghe

机构信息

Department of Medical Oncology and State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Signal Transduct Target Ther. 2023 Mar 19;8(1):118. doi: 10.1038/s41392-023-01322-w.

DOI:10.1038/s41392-023-01322-w
PMID:36935426
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10025258/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4cf/10025258/e8249b5f2021/41392_2023_1322_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4cf/10025258/e8249b5f2021/41392_2023_1322_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4cf/10025258/e8249b5f2021/41392_2023_1322_Fig1_HTML.jpg

相似文献

1
Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer.吡咯替尼联合卡培他滨可显著提高HER2阳性转移性乳腺癌患者的总生存期。
Signal Transduct Target Ther. 2023 Mar 19;8(1):118. doi: 10.1038/s41392-023-01322-w.
2
Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage.吡咯替尼联合卡培他滨对比拉帕替尼联合卡培他滨治疗中国 HER2 阳性转移性乳腺癌的成本-效果分析：基于医保覆盖情景的探讨
Curr Oncol. 2022 Aug 23;29(9):6053-6067. doi: 10.3390/curroncol29090476.
3
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.吡咯替尼联合卡培他滨对比拉帕替尼联合卡培他滨治疗人表皮生长因子受体 2 阳性转移性乳腺癌（PHOEBE）：一项多中心、开放标签、随机、对照、Ⅲ期临床试验。
Lancet Oncol. 2021 Mar;22(3):351-360. doi: 10.1016/S1470-2045(20)30702-6. Epub 2021 Feb 11.
4
Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.吡咯替尼治疗转移性 HER2 阳性乳腺癌的真实世界数据：拉帕替尼治疗后患者和脑转移患者疗效可观。
Cancer Res Treat. 2020 Oct;52(4):1059-1066. doi: 10.4143/crt.2019.633. Epub 2020 Apr 24.
5
Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases.吡咯替尼联合卡培他滨治疗 HER2 阳性乳腺癌脑转移的颅内疗效。
Drug Des Devel Ther. 2024 Mar 23;18:909-917. doi: 10.2147/DDDT.S451668. eCollection 2024.
6
Pyrotinib in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: A case report.吡咯替尼治疗人表皮生长因子受体2阳性转移性乳腺癌：1例报告
Medicine (Baltimore). 2020 Jun 19;99(25):e20809. doi: 10.1097/MD.0000000000020809.
7
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.吡咯替尼联合卡培他滨治疗人表皮生长因子受体 2 阳性转移性乳腺癌患者的安全性、有效性和生物标志物分析：一项 I 期临床试验。
Clin Cancer Res. 2019 Sep 1;25(17):5212-5220. doi: 10.1158/1078-0432.CCR-18-4173. Epub 2019 May 28.
8
Pyrotinib treatment enhances the radiosensitivity in HER2-positive brain metastatic breast cancer patients.吡咯替尼治疗增强 HER2 阳性脑转移乳腺癌患者的放射敏感性。
Anticancer Drugs. 2022 Jan 1;33(1):e622-e627. doi: 10.1097/CAD.0000000000001199.
9
Pyrotinib: First Global Approval.吡咯替尼：全球首次获批。
Drugs. 2018 Nov;78(16):1751-1755. doi: 10.1007/s40265-018-0997-0.
10
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial.吡咯替尼联合卡培他滨治疗人表皮生长因子受体 2 阳性乳腺癌伴脑转移患者（PERMEATE）：一项多中心、单臂、两队列、Ⅱ期临床试验。
Lancet Oncol. 2022 Mar;23(3):353-361. doi: 10.1016/S1470-2045(21)00716-6. Epub 2022 Jan 31.

引用本文的文献

1
Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial.HER2阳性乳腺癌患者曲妥珠单抗辅助治疗后使用吡咯替尼（PERSIST）：一项多中心II期试验。
Elife. 2025 Apr 3;13:RP101724. doi: 10.7554/eLife.101724.
2
A validated UPLC-MS/MS method for quantification of pyrotinib and population pharmacokinetic study of pyrotinib in HER2-positive breast cancer patients.一种用于定量吡咯替尼的经过验证的超高效液相色谱-串联质谱法及吡咯替尼在HER2阳性乳腺癌患者中的群体药代动力学研究。
Front Pharmacol. 2024 Sep 20;15:1432944. doi: 10.3389/fphar.2024.1432944. eCollection 2024.
3

本文引用的文献

1
Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer.吡咯替尼联合卡培他滨用于治疗HER2阳性复发或转移性乳腺癌的随机对照试验汇总分析及一线治疗方案的重新思考
Cancer Innov. 2022 Jul 14;1(2):119-123. doi: 10.1002/cai2.21. eCollection 2022 Aug.
2
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.曲妥珠单抗-德鲁替康与曲妥珠单抗-美坦新用于乳腺癌。
N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.
3
The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer.
Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial.
吡咯替尼联合曲妥珠单抗治疗协同克服 HER2 阳性乳腺癌的 HER2 依赖性：来自 PHILA 试验的见解。
EBioMedicine. 2024 Nov;109:105379. doi: 10.1016/j.ebiom.2024.105379. Epub 2024 Oct 4.
4
The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China.二线抗HER2治疗在HER-2阳性转移性患者中的价值：中国的成本效益分析
Front Pharmacol. 2024 Jul 12;15:1382120. doi: 10.3389/fphar.2024.1382120. eCollection 2024.
5
Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab.吡咯替尼治疗转移性乳腺癌的回顾性分析：与曲妥珠单抗联合使用疗效显著
Breast Cancer (Dove Med Press). 2024 May 25;16:253-268. doi: 10.2147/BCTT.S457845. eCollection 2024.
6
Pyrotinib and chrysin synergistically potentiate autophagy in HER2-positive breast cancer.吡咯替尼和白杨素协同增强 HER2 阳性乳腺癌的自噬作用。
Signal Transduct Target Ther. 2023 Dec 18;8(1):463. doi: 10.1038/s41392-023-01689-w.
酪氨酸激酶抑制剂在HER2阳性转移性乳腺癌治疗中的作用。
Eur J Cancer. 2021 Sep;154:175-189. doi: 10.1016/j.ejca.2021.06.026. Epub 2021 Jul 16.
4
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.吡咯替尼联合卡培他滨对比拉帕替尼联合卡培他滨治疗人表皮生长因子受体 2 阳性转移性乳腺癌（PHOEBE）：一项多中心、开放标签、随机、对照、Ⅲ期临床试验。
Lancet Oncol. 2021 Mar;22(3):351-360. doi: 10.1016/S1470-2045(20)30702-6. Epub 2021 Feb 11.
5
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.奈拉替尼联合卡培他滨对比拉帕替尼联合卡培他滨治疗曲妥珠单抗治疗后进展的 HER2 阳性转移性乳腺癌：NALA Ⅲ期临床试验。
J Clin Oncol. 2020 Sep 20;38(27):3138-3149. doi: 10.1200/JCO.20.00147. Epub 2020 Jul 17.
6
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.恩美曲妥珠单抗治疗既往 HER2 阳性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.
7
Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.吡咯替尼或拉帕替尼联合卡培他滨治疗既往接受紫杉类、蒽环类和/或曲妥珠单抗治疗的 HER2 阳性转移性乳腺癌：一项随机、Ⅱ期研究。
J Clin Oncol. 2019 Oct 10;37(29):2610-2619. doi: 10.1200/JCO.19.00108. Epub 2019 Aug 20.
8
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.吡咯替尼联合卡培他滨治疗人表皮生长因子受体 2 阳性转移性乳腺癌患者的安全性、有效性和生物标志物分析：一项 I 期临床试验。
Clin Cancer Res. 2019 Sep 1;25(17):5212-5220. doi: 10.1158/1078-0432.CCR-18-4173. Epub 2019 May 28.
9
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.曲妥珠单抗-美坦新偶联物对比卡培他滨加拉帕替尼用于既往治疗的 HER2 阳性晚期乳腺癌患者（EMILIA）：一项随机、开放标签、III 期试验的最终总生存结果的描述性分析。
Lancet Oncol. 2017 Jun;18(6):732-742. doi: 10.1016/S1470-2045(17)30312-1. Epub 2017 May 16.